We Embody a Legacy of Incredible Discoveries, Exploring the Boundaries of Innovation and Science
At Zenovel, we integrate our extensive expertise across a wide range of domains, from Good Clinical Practice to Regulatory Affairs, to present valuable insights and thought leadership. Each blog reflects our intense dedication to innovation, offering a forum to share our perspectives, groundbreaking ideas, and industry expertise. Through our blogs, we hope to uplift, inform, and support scientific, medical, and pharmaceutical innovation.
Regulatory affairs (RA) play a crucial role in the pharmaceutical industry; ensuring products meet quality, safety, and efficacy. As the
Navigating the world of pharmaceuticals, medical devices, and biotechnology is never straightforward. With the diversity of regulatory compliance governs the
The race to deliver life-saving therapies to patients is increasingly faster and more complex. Pharmaceutical and biotech companies are faced
In India, sponsors of clinical trials have vital responsibilities for the ethical, regulatory, and operational success of sponsored clinical trials.
In our fast-paced pharmaceutical industry, organizations can no longer operate their business by not only obtaining operational excellence, but also
Clinical trials are crucial for drug development, but managing them is complex due to the vast amount of data and
In the ever- changing pharmaceutical sector, studies of bioavailability (BA) and bioequivalence (BE) are essential to the approval of both name-brand and generic medications. BA/BE studies have grown in significance during the last thirty years, becoming essential for guaranteeing the safety and therapeutic effectiveness of pharmaceutical goods. Since these studies
Good Manufacturing Practices Audit: At Zenovel, we prioritizes maintaining high quality standards in the pharmaceutical supply chain through GMP audits, ensuring compliance with health authority regulations, industry best practices, and current standards. As regulatory requirements evolve, there’s a growing need for enhanced vigilance and Quality Risk Management during the audit
Overview of Regulatory Oversight in Life Sciences and Pharmaceutical Companies Regulatory agencies including the FDA, EMA, PMDA, HPRA, CDSCO, and others keep a vigilant eye on the life sciences and pharmaceutical sector. These organisations are committed to safeguarding patient safety and drug-product quality. In fiscal year 2023, the FDA
Understanding Nitrosamine Impurities in Pharmaceuticals: Nitrosamines, particularly N-nitrosamines, are probable or possible human carcinogens. They can form during the synthesis of active pharmaceutical ingredients (APIs) or during the storage of finished drug products. FDA guidance emphasizes the need for risk assessment, mitigation strategies, and regulatory compliance to control nitrosamine levels.
Introduction: In-process monitoring is a critical component of ensuring the quality and reliability of BA/BE studies, especially those involving drug-drug interactions (DDIs). For DDI studies, in-process monitoring is particularly crucial due to the complex nature of interactions, the need for precise data, and the potential impact on patient safety. Key
Abstract For the past few years, regulatory bodies, industry advocacy groups, and private companies have been tackling the concept of incorporating risk into the design of clinical trials and customizing monitoring strategies based on those risks to achieve higher-quality outcomes. Regulatory guidance like ICH and FDA encourag sponsors to adopt
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Write to us : bd@zenovel.com
Copyright © 2024 Zenovel. All rights reserved.
